07:00 , Jun 22, 2015 |  BC Week In Review  |  Company News

Besins Healthcare, Atossa Genetics deal

Besins granted Atossa exclusive, worldwide rights to develop and commercialize afimoxifene gel to treat and prevent hyperplasia of the breast. Besins is eligible to receive 8-9% royalties for 15 years after commercialization. Atossa also...
08:00 , Dec 13, 2004 |  BC Week In Review  |  Clinical News

4-OHT gel: Preliminary Phase II data

Preliminary data from a dose-ranging, double-blind, placebo-controlled, U.S. and European Phase II trial in 130 premenopausal women showed that transdermal administration of a 4mg dose of 4-OHT gel to the breast yielded a statistically significant...
08:00 , Dec 15, 2003 |  BC Week In Review  |  Clinical News

Tamogel: Phase II

In a French Phase II trial comparing Tamogel to oral tamoxifen or no therapy in 51 patients, Tamogel use for 2-3 weeks prior to surgery reduced tumor tissue proliferation in a dose-dependent manner and with...
07:00 , May 5, 2003 |  BC Week In Review  |  Clinical News

Tamogel: Phase II

Ascend began a dose-ranging, placebo-controlled international Phase II trial of Tamogel in about 100 healthy women with regular menstrual cycles who are not taking oral contraceptives. Ascend Therapeutics Inc., Herndon, Va.   Product: Tamogel   Business: Neurological...
07:00 , Jul 23, 2001 |  BC Week In Review  |  Company News

Tularik other research news

TLRK published in the Proceedings of the National Academy of Sciences the development of a fluorescence resonance energy transfer assay that allowed detection of 4-OHT, tamoxifen, and diethylstilbestrol (DES) binding to the orphan estrogen-related nuclear...